Oragenics, Inc. Shares Progress on Concussion Drug ONP-002
Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to creating new therapies for neurological disorders, has shared exciting updates regarding the development of its lead product, ONP-002, designed for treating concussions. This announcement follows significant advancements made throughout the year in preparation for Phase II clinical trials.
A Vision for Innovative Neurology
Oragenics is at the forefront of neurological therapy advancement with its groundbreaking intranasal technology aimed at revolutionizing drug delivery. The company's ONP-002 is a novel neurosteroid that offers a non-invasive and efficient solution for treating moderate to severe concussions, providing rapid delivery to the brain while minimizing systemic exposure.
The Urgent Need for Effective Concussion Treatments
Michael Redmond, President of Oragenics, emphasized the critical need for effective concussion therapies, stating that over three million concussions are recorded in the United States each year, with an astonishing global estimate of 69 million cases. Alarmingly, it’s believed that up to half of these cases remain unreported due to a lack of adequate treatment options. As such, the push toward the development of ONP-002 continues to gain momentum.
Significant Milestones in Development
This year has been transformative for Oragenics and its concussion drug as they navigate the various stages of drug development and trials. A few noteworthy milestones include:
1. Enhanced Clinical Team
In 2024, Oragenics strengthened its clinical leadership by appointing Dr. James “Jim” Kelly as Chief Medical Officer and Dr. William “Frank” Peacock as Chief Clinical Officer. Their extensive backgrounds in emergency medicine and brain health will guide the clinical development strategies for ONP-002.
2. Preparing for Phase II Trials
Building on successful Phase I results that confirmed the safety and tolerability of ONP-002, Oragenics is gearing up to launch Phase II trials. These new trials will focus on assessing the drug’s efficacy based on meaningful patient outcomes.
3. Safety Assessments Passed
Notably, ONP-002 has successfully navigated critical cardiotoxicity tests, reinforcing its safety profile by demonstrating a strong cardiac safety margin. Furthermore, it completed the necessary genotoxicity studies, confirming that it does not cause any damage to DNA.
4. Strategic Partnerships
The company has partnered with Avance Clinical, a leading clinical research organization, to enhance its capabilities for conducting Phase II trials. This collaboration allows Oragenics to leverage expert insights in clinical trial management and regulatory considerations.
5. Achieving Temperature Stability
An important milestone achieved by ONP-002 is its stability across various temperatures, making it feasible for use in diverse environments, such as sports or military settings, where concussions are common.
6. Ready-to-Use Delivery Devices
The company has completed the formulation of ONP-002 into a spray-dried powder and filled intranasal delivery devices for the impending Phase II trials, facilitating quick and direct treatment administration post-concussion.
7. Boosting Drug Delivery Efficiency
A cutting-edge formulation has improved the drug's absorption via the intranasal route, effectively increasing the amount of ONP-002 delivered per dose significant enough to enhance therapeutic outcomes.
Funding and Future Steps
In September 2024, Oragenics secured $4.45 million through a public offering, adding to a total of over $6 million raised this year. These funds are crucial for propelling the development of ONP-002 and further advancing its position in the market for concussion therapies.
Looking Ahead
Oragenics plans to initiate its Phase II clinical trials in the near future, initially focusing on sites in Australia before expanding to the U.S. Alongside this, they are developing emergency protocols for patient selection to ensure timely treatment, ideally within eight hours of injury.
Regulatory Milestones
A critical submission for the Australian regulatory review will be made soon, detailing the safety protocols and data collection methods needed to facilitate the trial approval process.
Commitment to Transparency
As Oragenics continues to progress towards innovative solutions for concussions, the company remains committed to open communication with its shareholders, providing continuous updates on their endeavors and milestones.
Frequently Asked Questions
What is ONP-002?
ONP-002 is a novel neurosteroid developed by Oragenics for treating moderate to severe concussions through an innovative intranasal delivery system.
When will Phase II trials begin?
The company anticipates beginning Phase II clinical trials soon, initially in Australia followed by trials in the U.S.
What recent achievements has Oragenics made in 2024?
Oragenics has strengthened its clinical team, secured funding, and achieved important safety milestones for ONP-002 in 2024.
Why is intranasal delivery important?
Intranasal delivery provides faster access to the brain, reducing systemic exposure and improving patient comfort compared to traditional methods.
How can interested investors stay informed?
Oragenics is committed to transparency and will continue to provide updates on clinical progress and company developments to its shareholders.
